NASDAQ: RKDAArcadia Biosciences Inc Stock
$1.90-0.16 (-7.77%)
Updated Apr 25, 2024
RKDA Price
$1.90
Fair Value Price
N/A
Market Cap
$2.59M
52 Week Low
$1.85
52 Week High
$7.30
P/E
-0.17x
P/B
0.2x
P/S
0.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.33M
Earnings
-$13.98M
Gross Margin
38.1%
Operating Margin
-262.16%
Profit Margin
-262.3%
Debt to Equity
0.55
Operating Cash Flow
-$15M
Beta
0.81
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RKDA Overview
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RKDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RKDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RKDA is good value based on its book value relative to its share price (0.2x), compared to the US Packaged Foods industry average (2.17x)
P/B vs Industry Valuation
RKDA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RKDA due diligence checks available for Premium users.
Be the first to know about important RKDA news, forecast changes, insider trades & much more!
RKDA News
Valuation
RKDA fair value
Fair Value of RKDA stock based on Discounted Cash Flow (DCF)
Price
$1.90
Fair Value
-$0.24
Undervalued by
877.30%
RKDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RKDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
8.56x
Market
40.97x
RKDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
2.17x
RKDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RKDA's financial health
Profit margin
Revenue
$1.2M
Net Income
-$2.9M
Profit Margin
-243.8%
RKDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RKDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.7M
Liabilities
$7.0M
Debt to equity
0.55
RKDA's short-term assets ($14.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RKDA's short-term assets ($14.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RKDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RKDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$52.0k
Financing
$0.0
RKDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RKDA vs Food Stocks
Arcadia Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.